Multiple studies have shown the therapeutic value of anti-CTLA-4, anti-PD-1/L1 and their combination, with or without chemotherapy in metastatic or advanced NSCLC (Table 2) [116,117,118,119,120,121,122,123]. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.